Current Report Filing (8-k)
December 11 2017 - 9:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 11, 2017
PUMA BIOTECHNOLOGY, INC.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware
|
|
001-35703
|
|
77-0683487
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
10880 Wilshire Boulevard, Suite 2150
Los Angeles, California 90024
(Address of principal executive offices) (Zip Code)
(424)
248-6500
(Registrants telephone number, including area code)
N/A
(Former name or
former address, if changed since last report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of
this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On December 11, 2017, Puma Biotechnology, Inc. (the
Company) announced that the European Patent Office has upheld the claims in the Companys licensed European patent (EP 2416774). The granted claims in European patent (EP 2416774) cover, inter alia, the use of neratinib in extended
adjuvant treatment of early stage HER2 overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
PUMA BIOTECHNOLOGY, INC.
|
|
|
|
|
Date: December 11, 2017
|
|
|
|
By:
|
|
/s/ Alan H. Auerbach
|
|
|
|
|
|
|
Alan H. Auerbach
|
|
|
|
|
|
|
Chief Executive Officer and President
|
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Sep 2023 to Sep 2024